Clinical Trials Directory

Trials / Completed

CompletedNCT01188694

Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
42 (actual)
Sponsor
University of Washington · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Posttraumatic stress disorder (PTSD) is a condition that involves intense memories of a traumatic event and intense, persistent feelings of anxiety. There are several effective therapies for PTSD, but they are often time consuming. The investigators want to see if the investigators can shorten treatment time while keeping therapy effective by adding a medication called methylene blue, USP, taken orally as a pill, to the therapy. The specific aims are: 1) To see whether medication plus psychotherapy improves PTSD symptoms more than placebo plus psychotherapy or a waitlist; 2) To examine the long-term outcome of those receiving medication plus psychotherapy 1 and 3 months after treatment has ended; 3) To examine whether medication plus psychotherapy helps with depression, trauma-related cognitions, and functioning.

Detailed description

The psychotherapy the investigators are offering in this study is a type of cognitive behavioral therapy called imaginal exposure. In imaginal exposure, the investigators encourage the client to approach the memory of the trauma by recounting the trauma story to the therapist and discussing his or her reactions to the memory.

Conditions

Interventions

TypeNameDescription
DRUGPsychotherapy plus Methylene Blue, USPThis treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.
BEHAVIORALPsychotherapy plus PlaceboThis treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, capsules containing the placebo will be given.
BEHAVIORALDelayed PsychotherapyIndividuals must wait approximately five to six weeks to start treatment. They will come in for two check-in appointments before starting treatment. Treatment will consist of ten twice-weekly psychotherapy sessions (90-120 min each session).

Timeline

Start date
2009-09-01
Primary completion
2013-04-01
Completion
2013-04-01
First posted
2010-08-25
Last updated
2017-06-14
Results posted
2017-06-14

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01188694. Inclusion in this directory is not an endorsement.